Targeting the insulin-like growth factor pathway in hepatocellular carcinoma

World Journal of Hepatology

Volumn 6, Issue 10, 2014, Pages 716-737

  Enguita Germán, Mónica ^a   Fortes, Puri ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Antibody therapy; Hepatocellular carcinoma; Insulin; Insulin like growth factor receptor; Insulinlike growth factor; Therapy; Tyrosine kinase inhibitor

Indexed keywords

EID: 84909991205     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i10.716     Document Type: Review

References (236)

1. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulinlike growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75: 59-72 [PMID: 8402901 DOI: 10.1016/0092-8674(93)90679-K]
2. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489 [PMID: 10995803 DOI: 10.1093/jnci/92.18.1472]
3. Marshman E, Streuli CH. Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 2002; 4: 231-239 [PMID: 12473169 DOI: 10.1387/ijdb.113364as]
4. Daughaday WH, Hall K, Raben MS, Salmon WD, van den Brande JL, van Wyk JJ. Somatomedin: proposed designation for sulphation factor. Nature 1972; 235: 107 [PMID: 4550398 DOI: 10.1038/235107a0]
5. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-2776 [PMID: 632300]
6. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev 2005; 26: 19-39 [PMID: 16278749]
7. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009; 30: 586-623 [PMID: 19752219 DOI: 10.1210/er.2008-0047]
8. Malaguarnera R, Belfiore A. The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) 2011; 2: 93 [PMID: 22654833 DOI: 10.3389/fendo.2011.00093]
9. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 2000; 278: E967-E976 [PMID: 10826997]
10. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 2002; 175: 19-31 [PMID: 12379487 DOI: 10.1677/joe.0.1750019]
11. Sarfstein R, Werner H. Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology 2013; 154: 1672-1679 [PMID: 23507573 DOI: 10.1210/en.2012-2165]
12. Brogiolo W, Stocker H, Ikeya T, Rintelen F, Fernandez R, Hafen E. An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol 2001; 11: 213-221 [PMID: 11250149 DOI: 10.1016/S0960-9822(01)00068-9]
13. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928 [PMID: 19029956 DOI: 10.1038/nrc2536]
14. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, Le-Roith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96: 7324-7329 [PMID: 10377413 DOI: 10.1073/pnas.96.13.7324]
15. Jansson JO, Edén S, Isaksson O. Sexual dimorphism in the control of growth hormone secretion. Endocr Rev 1985; 6: 128-150 [PMID: 2861084 DOI: 10.1210/edrv-6-2-128]
16. Herrington J, Smit LS, Schwartz J, Carter-Su C. The role of STAT proteins in growth hormone signaling. Oncogene 2000; 19: 2585-2597 [PMID: 10851057 DOI: 10.1038/sj.onc.1203526]
17. Woelfle J, Billiard J, Rotwein P. Acute control of insulinlike growth factor-I gene transcription by growth hormone through Stat5b. J Biol Chem 2003; 278: 22696-22702 [PMID: 12682066 DOI: 10.1074/jbc.M301362200]
18. LeRoith D, Roberts CT. Insulin-like growth factors. Ann N Y Acad Sci 1993; 692: 1-9 [PMID: 8215015 DOI: 10.1111/j.1749-6632.1993.tb26200.x]
19. Lund PK. Insulin-like growth factor I: molecular biology and relevance to tissue-specific expression and action. Recent Prog Horm Res 1994; 49: 125-148 [PMID: 7511825]
20. Zhang J, Whitehead RE, Underwood LE. Effect of fasting on insulin-like growth factor (IGF)-IA and IGF-IB messenger ribonucleic acids and prehormones in rat liver. Endocrinology 1997; 138: 3112-3118 [PMID: 9231757 DOI: 10.1210/en.138.8.3112]
21. Pell JM, Saunders JC, Gilmour RS. Differential regulation of transcription initiation from insulin-like growth factor-I (IGF-I) leader exons and of tissue IGF-I expression in response to changed growth hormone and nutritional status in sheep. Endocrinology 1993; 132: 1797-1807 [PMID: 8462477 DOI: 10.1210/en.132.4.1797]
22. Brameld JM, Atkinson JL, Saunders JC, Pell JM, Buttery PJ, Gilmour RS. Effects of growth hormone administration and dietary protein intake on insulin-like growth factor I and growth hormone receptor mRNA Expression in porcine liver, skeletal muscle, and adipose tissue. J Anim Sci 1996; 74: 1832-1841 [PMID: 8856437]
23. Rotwein P, Pollock KM, Didier DK, Krivi GG. Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulinlike growth factor I precursor peptides. J Biol Chem 1986; 261: 4828-4832 [PMID: 2937782]
24. Duguay SJ, Milewski WM, Young BD, Nakayama K, Steiner DF. Processing of wild-type and mutant proinsulin-like growth factor-IA by subtilisin-related proprotein convertases. J Biol Chem 1997; 272: 6663-6670 [PMID: 9045697 DOI: 10.1074/jbc.272.10.6663]
25. Annunziata M, Granata R, Ghigo E. The IGF system. Acta Diabetol 2011; 48: 1-9 [PMID: 21042815 DOI: 10.1007/s00592-010-0227-z]
26. Cohick WS, Clemmons DR. The insulin-like growth factors. Annu Rev Physiol 1993; 55: 131-153 [PMID: 8466170 DOI: 10.1146/annurev.ph.55.030193.001023]
27. Ohlsson C, Mohan S, Sjögren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009; 30: 494-535 [PMID: 19589948 DOI: 10.1210/er.2009-0010]
28. Scharf JG, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol 2001; 54: 138-144 [PMID: 11376124 DOI: 10.1136/mp.54.3.138]
29. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55: 249-252 [PMID: 7812953]
30. Lelbach A, Muzes G, Feher J. The insulin-like growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases. Acta Physiol Hung 2005; 92: 97-107 [PMID: 16268048 DOI: 10.1556/APhysiol.92.2005.2.1]
31. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science 1981; 212: 1279-1281 [PMID: 6262917 DOI: 10.1126/science.6262917]
32. Blakesley VA, Scrimgeour A, Esposito D, Le Roith D. Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Cytokine Growth Factor Rev 1996; 7: 153-159 [PMID: 8899293 DOI: 10.1016/1359-6101(96)00015-9]
33. Rao LV, Wikarczuk ML, Heyner S. Functional roles of insulin and insulinlike growth factors in preimplantation mouse embryo development. In Vitro Cell Dev Biol 1990; 26: 1043-1048 [PMID: 1703523 DOI: 10.1007/BF02624438]
34. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34 [PMID: 7758431]
35. Brissenden JE, Ullrich A, Francke U. Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor. Nature 1984; 310: 781-784 [PMID: 6382023 DOI: 10.1038/310781a0]
36. Giannoukakis N, Deal C, Paquette J, Goodyer CG, Polychronakos C. Parental genomic imprinting of the human IGF2 gene. Nat Genet 1993; 4: 98-101 [PMID: 8099843 DOI: 10.1038/ng0593-98]
37. Wu J, Qin Y, Li B, He WZ, Sun ZL. Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma. Genomics 2008; 91: 443-450 [PMID: 18358696 DOI: 10.1016/j.ygeno.2008.01.007]
38. Vu TH, Hoffman AR. Promoter-specific imprinting of the human insulin-like growth factor-II gene. Nature 1994; 371: 714-717 [PMID: 7935819 DOI: 10.1038/371714a0]
39. Sussenbach JS, Rodenburg RJ, Scheper W, Holthuizen P. Transcriptional and post-transcriptional regulation of the human IGF-II gene expression. Adv Exp Med Biol 1993; 343: 63-71 [PMID: 8184744]
40. O'Dell SD, Day IN. Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol 1998; 30: 767-771 [PMID: 9722981 DOI: 10.1016/S1357-2725(98)00048-X]
41. Sussenbach JS, Steenbergh PH, Holthuizen P. Structure and expression of the human insulin-like growth factor genes. Growth Regul 1992; 2: 1-9 [PMID: 1486331]
42. Yaseen MA, Wrenzycki C, Herrmann D, Carnwath JW, Niemann H. Changes in the relative abundance of mRNA transcripts for insulin-like growth factor (IGF-I and IGF-II) ligands and their receptors (IGF-IR/IGF-IIR) in preimplantation bovine embryos derived from different in vitro systems. Reproduction 2001; 122: 601-610 [PMID: 11570968 DOI: 10.1530/rep.0.1220601]
43. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989; 10: 68-91 [PMID: 2666112]
44. Oka Y, Rozek LM, Czech MP. Direct demonstration of rapid insulin-like growth factor II Receptor internalization and recycling in rat adipocytes. Insulin stimulates 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process. J Biol Chem 1985; 260: 9435-9442 [PMID: 2991246]
45. Sacco A, Morcavallo A, Pandini G, Vigneri R, Belfiore A. Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinology 2009; 150: 3594-3602 [PMID: 19443570 DOI: 10.1210/en.2009-0377]
46. Sciacca L, Prisco M, Wu A, Belfiore A, Vigneri R, Baserga R. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology 2003; 144: 2650-2658 [PMID: 12746329 DOI: 10.1210/en.2002-0136]
47. Denley A, Wallace JC, Cosgrove LJ, Forbes BE. The insulin receptor isoform exon 11-(IR-A) in cancer and other diseases: a review. Horm Metab Res 2003; 35: 778-785 [PMID: 14710358 DOI: 10.1055/s-2004-814157]
48. Varewijck AJ, Janssen JA. Insulin and its analogues and their affinities for the IGF1 receptor. Endocr Relat Cancer 2012; 19: F63-F75 [PMID: 22420005 DOI: 10.1530/ERC-12-0026]
49. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163 [PMID: 7540132]
50. Siddle K, Ursø B, Niesler CA, Cope DL, Molina L, Surinya KH, Soos MA. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 2001; 29: 513-525 [PMID: 11498020 DOI: 10.1042/BST0290513]
51. Rosenfeld RG, Lamson G, Pham H, Oh Y, Conover C, De Leon DD, Donovan SM, Ocrant I, Giudice L. Insulinlike growth factor-binding proteins. Recent Prog Horm Res 1990; 46: 99-159; discussion 159-163 [PMID: 1704143]
52. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factorbinding protein (IGFBP) superfamily. Endocr Rev 1999; 20: 761-787 [PMID: 10605625 DOI: 10.1210/er.20.6.761]
53. Wu J, Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol 2011; 4: 30 [PMID: 21729319 DOI: 10.1186/1756-8722-4-30]
54. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997; 8: 45-62 [PMID: 9174662 DOI: 10.1016/S1359-6101(96)00053-6]
55. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factorbinding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801-831 [PMID: 9408744 DOI: 10.1210/er.18.6.801]
56. Baxter RC. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand Suppl 1991; 372: 107-114; discussion 115 [PMID: 1718141 DOI: 10.1111/j.1651-2227.1991.tb17983.x]
57. Rechler MM, Clemmons DR. Regulatory Actions of Insulinlike Growth Factor-binding Proteins. Trends Endocrinol Metab 1998; 9: 176-183 [PMID: 18406262 DOI: 10.1016/S1043-2760(98)00047-2]
58. Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989; 121: 753-758 [PMID: 2558477]
59. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998; 140: 19-24 [PMID: 9722163 DOI: 10.1016/S0303-7207(98)00024-0]
60. Arai T, Busby W, Clemmons DR. Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 1996; 137: 4571-4575 [PMID: 8895319 DOI: 10.1210/en.137.11.4571]
61. Jones JI, D'Ercole AJ, Camacho-Hubner C, Clemmons DR. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci USA 1991; 88: 7481-7485 [PMID: 1715565 DOI: 10.1073/pnas.88.17.7481]
62. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer 2006; 13 Suppl 1: S33-S43 [PMID: 17259557 DOI: 10.1677/erc.1.01280]
63. Roth RA, Kiess W. Insulin-like growth factor receptors: recent developments and new methodologies. Growth Regul 1994; 4 Suppl 1: 31-38 [PMID: 8205066]
64. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505-518 [PMID: 15229476 DOI: 10.1038/nrc1387]
65. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274 [PMID: 17604717 DOI: 10.1016/j.cell.2007.06.009]
66. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29: 233-242 [PMID: 15130559 DOI: 10.1016/j.tibs.2004.03.006]
67. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev 2006; 17: 305-323 [PMID: 16621671 DOI: 10.1016/j.cytogfr.2006.02.002]
68. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, Inoki K, Guan KL, Brosius FC. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 2008; 295: C836-C843 [PMID: 18650261 DOI: 10.1152/ajpcell.00554.2007]
69. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789 [PMID: 8524413 DOI: 10.1038/378785a0]
70. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 1998; 273: 13150-13156 [PMID: 9582355 DOI: 10.1074/jbc.273.21.13150]
71. Rössig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 2001; 21: 5644-5657 [PMID: 11463845 DOI: 10.1128/MCB.21.16.5644-5657.2001]
72. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-1123 [PMID: 19620249 DOI: 10.1677/ERC-09-0087]
73. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22 [PMID: 12509763 DOI: 10.1038/nrc969]
74. Shelton JG, Steelman LS, White ER, McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 2004; 3: 372-379 [PMID: 14726697 DOI: 10.4161/cc.3.3.747]
75. Héron-Milhavet L, Karas M, Goldsmith CM, Baum BJ, LeRoith D. Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem 2001; 276: 18185-18192 [PMID: 11278917 DOI: 10.1074/jbc.M011490200]
76. Galvan V, Logvinova A, Sperandio S, Ichijo H, Bredesen DE. Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1). J Biol Chem 2003; 278: 13325-13332 [PMID: 12556535 DOI: 10.1074/jbc.M211398200]
77. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999; 19: 7203-7215 [PMID: 10490655]
78. Chaves J, Saif MW. IGF system in cancer: from bench to clinic. Anticancer Drugs 2011; 22: 206-212 [PMID: 21178765 DOI: 10.1097/CAD.0b013e32834258a1]
79. Yadav A, Kalita A, Dhillon S, Banerjee K. JAK/STAT3 pathway is involved in survival of neurons in response to insulinlike growth factor and negatively regulated by suppressor of cytokine signaling-3. J Biol Chem 2005; 280: 31830-31840 [PMID: 15998644 DOI: 10.1074/jbc.M501316200]
80. Mills JJ, Falls JG, De Souza AT, Jirtle RL. Imprinted M6p/Igf2 receptor is mutated in rat liver tumors. Oncogene 1998; 16: 2797-2802 [PMID: 9652747 DOI: 10.1038/sj.onc.1201801]
81. Barlow DP, Stöger R, Herrmann BG, Saito K, Schweifer N. The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. Nature 1991; 349: 84-87 [PMID: 1845916 DOI: 10.1038/349084a0]
82. Xu Y, Goodyer CG, Deal C, Polychronakos C. Functional polymorphism in the parental imprinting of the human IGF2R gene. Biochem Biophys Res Commun 1993; 197: 747-754 [PMID: 8267611 DOI: 10.1006/bbrc.1993.2542]
83. Kalscheuer VM, Mariman EC, Schepens MT, Rehder H, Ropers HH. The insulin-like growth factor type-2 receptor gene is imprinted in the mouse but not in humans. Nat Genet 1993; 5: 74-78 [PMID: 8220428 DOI: 10.1038/ng0993-74]
84. Killian JK, Jirtle RL. Genomic structure of the human M6P/IGF2 receptor. Mamm Genome 1999; 10: 74-77 [PMID: 9892739 DOI: 10.1007/s003359900947]
85. Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, Rutter WJ. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 1987; 329: 301-307 [PMID: 2957598 DOI: 10.1038/329301a0]
86. Gary-Bobo M, Nirdé P, Jeanjean A, Morère A, Garcia M. Mannose 6-phosphate receptor targeting and its applications in human diseases. Curr Med Chem 2007; 14: 2945-2953 [PMID: 18220730 DOI: 10.2174/092986707782794005]
87. Braulke T. Type-2 IGF receptor: a multi-ligand binding protein. Horm Metab Res 1999; 31: 242-246 [PMID: 10226808 DOI: 10.1055/s-2007-978725]
88. Espelund U, Bruun JM, Richelsen B, Flyvbjerg A, Frystyk J. Pro-and mature IGF-II during diet-induced weight loss in obese subjects. Eur J Endocrinol 2005; 153: 861-869 [PMID: 16322392 DOI: 10.1530/eje.1.02028]
89. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995; 11: 447-449 [PMID: 7493029 DOI: 10.1038/ng1295-447]
90. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995; 10: 1725-1729 [PMID: 7753549]
91. Clairmont KB, Czech MP. Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor. J Biol Chem 1991; 266: 12131-12134 [PMID: 1648081]
92. Costello M, Baxter RC, Scott CD. Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum: measurement by enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 1999; 84: 611-617 [PMID: 10022425 DOI: 10.1210/jc.84.2.611]
93. Denley A, Bonython ER, Booker GW, Cosgrove LJ, Forbes BE, Ward CW, Wallace JC. Structural determinants for highaffinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol 2004; 18: 2502-2512 [PMID: 15205474 DOI: 10.1210/me.2004-0183]
94. Morrione A, Valentinis B, Xu SQ, Yumet G, Louvi A, Efstratiadis A, Baserga R. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci USA 1997; 94: 3777-3782 [PMID: 9108054]
95. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19: 3278-3288 [PMID: 10207053]
96. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-169 [PMID: 22337149 DOI: 10.1038/nrc3215]
97. Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R, Belfiore A. Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology 2012; 153: 2152-2163 [PMID: 22355074 DOI: 10.1210/en.2011-1843]
98. Blanquart C, Achi J, Issad T. Characterization of IRA/IRB hybrid insulin receptors using bioluminescence resonance energy transfer. Biochem Pharmacol 2008; 76: 873-883 [PMID: 18718450 DOI: 10.1016/j.bcp.2008.07.027]
99. Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 1993; 290 (Pt 2): 419-426 [PMID: 8452530]
100. Soos MA, Whittaker J, Lammers R, Ullrich A, Siddle K. Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochem J 1990; 270: 383-390 [PMID: 1698059]
101. Bailyes EM, Navé BT, Soos MA, Orr SR, Hayward AC, Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 1997; 327 (Pt 1): 209-215 [PMID: 9355755]
102. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277: 39684-39695 [PMID: 12138094 DOI: 10.1074/jbc.M202766200]
103. Cornellà H, Alsinet C, Villanueva A. Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res 2011; 35: 821-825 [PMID: 21303380 DOI: 10.1111/j.1530-0277.2010.01406.x]
104. Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 2006; 387: 349-360 [PMID: 16606331 DOI: 10.1515/BC.2006.047]
105. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218 [PMID: 15690074 DOI: 10.1172/JCI24282]
106. Reeves HL, Friedman SL. Activation of hepatic stellate cells--a key issue in liver fibrosis. Front Biosci 2002; 7: d808-d826 [PMID: 11897564 DOI: 10.2741/reeves]
107. Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 2009; 120: 361-368 [PMID: 19768189]
108. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012; 56: 769-775 [PMID: 22378017 DOI: 10.1002/hep.25670]
109. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013; 10: 34-42 [PMID: 23147664 DOI: 10.1038/nrgastro.2012.199]
110. Colnot S, Fortes P. Editing liver tumours. Gut 2014; 63: 709-710 [PMID: 23878166 DOI: 10.1136/gutjnl-2013-305334]
111. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-1558 [PMID: 23539594 DOI: 10.1126/science. 1235122]
112. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687 [PMID: 16929323 DOI: 10.1038/nrc1934]
113. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-8108 [PMID: 16258107 DOI: 10.1200/JCO.2004.00.1537]
114. Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14: 1-14 [PMID: 18176955]
115. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284 [PMID: 17126425 DOI: 10.1016/j.bbamcr.2006.10.001]
116. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012; 3: 954-987 [PMID: 23006971]
117. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-1440 [PMID: 10573522 DOI: 10.1002/hep.510300629]
118. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1]
119. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006; 25: 3866-3884 [PMID: 16799628 DOI: 10.1038/sj.onc.1209550]
120. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140 [PMID: 18852116 DOI: 10.1158/1535-7163.MCT-08-0013]
121. Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res 2013; 43: 147-154 [PMID: 23145926 DOI: 10.1111/j.1872-034X.2012.01113.x]
122. Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 2010; 21: 326-332 [PMID: 20016366 DOI: 10.1097/CAD.0b013e3283350e26]
123. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63 [PMID: 23182627 DOI: 10.1016/S1470-2045(12)70490-4]
124. Trojan J, Zeuzem S. Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs 2013; 22: 141-147 [PMID: 23167786 DOI: 10.1517/13543784.2013.741586]
125. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012; 3: 236-260 [PMID: 22470194]
126. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011; 21: 35-43 [PMID: 20946957 DOI: 10.1016/j.semcancer.2010.10.007]
127. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 2009; 100: 1-8 [PMID: 19038007 DOI: 10.1111/j.1349-7006.2008.01006.x]
128. Fernández-Rodriguez CM, Prada I, Andrade A, Moreiras M, Guitián R, Aller R, Lledó JL, Cacho G, Quiroga J, Prieto J. Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis. Dig Dis Sci 2001; 46: 1313-1320 [PMID: 11414310]
129. Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta GB, Caporaso N, Carella C. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 2002; 95: 2539-2545 [PMID: 12467068 DOI: 10.1002/cncr.11002]
130. Su WW, Lee KT, Yeh YT, Soon MS, Wang CL, Yu ML, Wang SN. Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal 2010; 24: 195-200 [PMID: 20486202 DOI: 10.1002/jcla.20320]
131. Su TS, Liu WY, Han SH, Jansen M, Yang-Fen TL, P'eng FK, Chou CK. Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res 1989; 49: 1773-1777 [PMID: 2466561]
132. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011; 29: 3892-3899 [PMID: 21911725 DOI: 10.1200/JCO.2011.36.0636]
133. Cho E, Kim HC, Lee JH, Jeong-Ju Yoo WM, Cho YY, Lee MJ, Cho Y, Lee DH, Lee YB, Yu SJ, Kim YJ, Yoon JH, Chung JW, Kim CY, Lee HS. Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization. PLoS One 2014; 9: e90862 [PMID: 24595361 DOI: 10.1371/journal.pone.0090862]
134. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004 [PMID: 18923165 DOI: 10.1056/NEJMoa0804525]
135. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010; 16: 4688-4694 [PMID: 20713493 DOI: 10.1158/1078-0432.CCR-09-1811]
136. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005 [PMID: 20639898 DOI: 10.1038/onc.2010.236]
137. Schirmacher P, Held WA, Yang D, Chisari FV, Rustum Y, Rogler CE. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 1992; 52: 2549-2556 [PMID: 1568224]
138. Breuhahn K, Vreden S, Haddad R, Beckebaum S, Stippel D, Flemming P, Nussbaum T, Caselmann WH, Haab BB, Schirmacher P. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 2004; 64: 6058-6064 [PMID: 15342387 DOI: 10.1158/0008-5472.CAN-04-0292]
139. Lund P, Schubert D, Niketeghad F, Schirmacher P. Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett 2004; 206: 85-96 [PMID: 15019164 DOI: 10.1016/j.canlet.2003.10.018]
140. Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q, Li T, Hoffman AR. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 2003; 111: 265-273 [PMID: 12531883 DOI: 10.1172/JCI15109]
141. El Tayebi HM, Hosny KA, Esmat G, Breuhahn K, Abdelaziz AI. miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Lett 2012; 586: 3309-3316 [PMID: 22819824 DOI: 10.1016/j.febslet.2012.06.054]
142. Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH, Meng XY. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol 2005; 11: 4655-4660 [PMID: 16094705]
143. Qian J, Yao D, Dong Z, Wu W, Qiu L, Yao N, Li S, Bian Y, Wang Z, Shi G. Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol 2010; 134: 799-806 [PMID: 20959664 DOI: 10.1309/AJCPTFDSE2V3-LCZP]
144. Yun K, Jinno Y, Sohda T, Niikawa N, Ikeda T. Promoterspecific insulin-like growth factor 2 gene imprinting in human fetal liver and hepatoblastoma. J Pathol 1998; 185: 91-98 [PMID: 9713365]
145. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR, Feinberg AP. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299: 1753-1755 [PMID: 12637750 DOI: 10.1126/science.1080902]
146. Kim HT, Choi BH, Niikawa N, Lee TS, Chang SI. Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors. Am J Med Genet 1998; 80: 391-395 [PMID: 9856569]
147. van Roozendaal CE, Gillis AJ, Klijn JG, van Ooijen B, Claassen CJ, Eggermont AM, Henzen-Logmans SC, Oosterhuis JW, Foekens JA, Looijenga LH. Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Lett 1998; 437: 107-111 [PMID: 9804181 DOI: 10.1016/S0014-5793(98)01211-3]
148. Poirier K, Chalas C, Tissier F, Couvert P, Mallet V, Carrié A, Marchio A, Sarli D, Gicquel C, Chaussade S, Beljord C, Chelly J, Kerjean A, Terris B. Loss of parental-specific methylation at the IGF2 locus in human hepatocellular carcinoma. J Pathol 2003; 201: 473-479 [PMID: 14595760 DOI: 10.1002/path.1477]
149. Li X, Nong Z, Ekström C, Larsson E, Nordlinder H, Hofmann WJ, Trautwein C, Odenthal M, Dienes HP, Ekström TJ, Schirmacher P. Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 1997; 57: 2048-2054 [PMID: 9158004]
150. Fiorentino M, Grigioni WF, Baccarini P, D'Errico A, De Mitri MS, Pisi E, Mancini AM. Different in situ expression of insulin-like growth factor type II in hepatocellular carcinoma. An in situ hybridization and immunohistochemical study. Diagn Mol Pathol 1994; 3: 59-65 [PMID: 8162257 DOI: 10.1097/00019606-199403010-00010]
151. Couvert P, Carrié A, Pariès J, Vaysse J, Miroglio A, Kerjean A, Nahon P, Chelly J, Trinchet JC, Beaugrand M, Ganne-Carrié N. Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma. World J Gastroenterol 2008; 14: 5419-5427 [PMID: 18803353 DOI: 10.3748/wjg.14.5419]
152. Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM, Aggarwal D. Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 2004; 80: 1106-1122 [PMID: 15531656]
153. Ubagai T, Kikuchi T, Fukusato T, Ono Y. Aflatoxin B1 modulates the insulin-like growth factor-2 dependent signaling axis. Toxicol In Vitro 2010; 24: 783-789 [PMID: 20036727 DOI: 10.1016/j.tiv.2009.12.022]
154. Lee YI, Lee S, Das GC, Park US, Park SM, Lee YI. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-offunction during the formation of hepatocellular carcinoma. Oncogene 2000; 19: 3717-3726 [PMID: 10949925 DOI: 10.1038/sj.onc.1203694]
155. Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng KC, Liu YF, Yeh YH, Su SC, Chen YC, Chen MK, Yang SF. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 2010; 17: 1808-1815 [PMID: 20119675 DOI: 10.1245/s10434-009-0904-8]
156. Chao LT, Wu CF, Sung FY, Lin CL, Liu CJ, Huang CJ, Tsai KS, Yu MW. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year followup of a population-based cohort. Carcinogenesis 2011; 32: 876-881 [PMID: 21464041 DOI: 10.1093/carcin/bgr058]
157. Huynh H, Chow PK, Ooi LL, Soo KC. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 2002; 13: 115-122 [PMID: 11959812]
158. Scharf JG, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T, Hartmann H. Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis 1998; 19: 2121-2128 [PMID: 9886566 DOI: 10.1093/carcin/19.12.2121]
159. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against druginduced apoptosis. Biochem Pharmacol 2004; 68: 1003-1015 [PMID: 15313394 DOI: 10.1016/j.bcp.2004.05.029]
160. Aleem E, Elshayeb A, Elhabachi N, Mansour AR, Gowily A, Hela A. Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection. Oncol Lett 2012; 3: 704-712 [PMID: 22740980 DOI: 10.3892/ol.2011.546]
161. Domené HM, Hwa V, Argente J, Wit JM, Camacho-Hübner C, Jasper HG, Pozo J, van Duyvenvoorde HA, Yakar S, Fofanova-Gambetti OV, Rosenfeld RG. Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res 2009; 72: 129-141 [PMID: 19729943 DOI: 10.1159/000232486]
162. Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B, Hoffmann K, Ehemann V, Schemmer P, Schirmacher P, Lorenzo Bermejo J, Longerich T. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 2012; 56: 1817-1827 [PMID: 22689435 DOI: 10.1002/hep.25870]
163. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, Taniyama M, Nakamura S, Uemura M, Takuma Y, Yumoto E, Higashi T, Tsuji T. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 2002; 176: 149-158 [PMID: 11804742 DOI: 10.1016/S0304-3835(01)00736-4]
164. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-649 [PMID: 7566179 DOI: 10.1038/377646a0]
165. Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, Mills AS, Waxman S, Fisher RA, Llovet JM, Fisher PB, Sarkar D. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 2009; 119: 465-477 [PMID: 19221438 DOI: 10.1172/JCI36460]
166. Chen D, Yoo BK, Santhekadur PK, Gredler R, Bhutia SK, Das SK, Fuller C, Su ZZ, Fisher PB, Sarkar D. Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma. Clin Cancer Res 2011; 17: 6693-6701 [PMID: 21908579 DOI: 10.1158/1078-0432. CCR-10-2774]
167. Li F, Fan YC, Gao S, Sun FK, Yang Y, Wang K. Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma. Genes Chromosomes Cancer 2014; 53: 90-97 [PMID: 24142767 DOI: 10.1002/gcc.22120]
168. Ranke MB, Maier KP, Schweizer R, Stadler B, Schleicher S, Elmlinger MW, Flehmig B. Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res 2003; 60: 174-180 [PMID: 14530605]
169. Umemura A, Itoh Y, Itoh K, Yamaguchi K, Nakajima T, Higashitsuji H, Onoue H, Fukumoto M, Okanoue T, Fujita J. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology 2008; 47: 493-502 [PMID: 18161051 DOI: 10.1002/hep.22027]
170. Brouillet JP, Hanslick B, Maudelonde T, Pivat MT, Grenier J, Blanc F, Rochefort H. Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer. Clin Biochem 1991; 24: 491-496 [PMID: 1663431 DOI: 10.1016/S0009-9120(05)80008-6]
171. Martin DC, Fowlkes JL, Babic B, Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol 1999; 146: 881-892 [PMID: 10459021 DOI: 10.1083/jcb.146.4.881]
172. Aleem E, Nehrbass D, Klimek F, Mayer D, Bannasch P. Upregulation of the insulin receptor and type I insulin-like growth factor receptor are early events in hepatocarcinogenesis. Toxicol Pathol 2011; 39: 524-543 [PMID: 21411721 DOI: 10.1177/0192623310396905]
173. Kasprzak A, Adamek A. The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (review). Int J Oncol 2012; 41: 1919-1931 [PMID: 23076735 DOI: 10.3892/ijo.2012.1666]
174. Faivre S, Bouattour M, Raymond E. Novel molecular therapies in hepatocellular carcinoma. Liver Int 2011; 31 Suppl 1: 151-160 [PMID: 21205154 DOI: 10.1111/j.1478-3231.2010.02395.x]
175. Tanaka S, Wands JR. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 1996; 56: 3391-3394 [PMID: 8758899]
176. Boissan M, Beurel E, Wendum D, Rey C, Lécluse Y, Housset C, Lacombe ML, Desbois-Mouthon C. Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 2005; 167: 869-877 [PMID: 16127164 DOI: 10.1016/S0002-9440(10)62058-5]
177. Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, Wands JR. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006; 44: 446-457 [PMID: 16871543 DOI: 10.1002/hep.21272]
178. Ma Y, Kong Q, Hua H, Luo T, Jiang Y. Aflatoxin B1 up-regulates insulin receptor substrate 2 and stimulates hepatoma cell migration. PLoS One 2012; 7: e47961 [PMID: 23112878 DOI: 10.1371/journal.pone.0047961]
179. Martin-Kleiner I, Gall Troselj K. Mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) in carcinogenesis. Cancer Lett 2010; 289: 11-22 [PMID: 19646808 DOI: 10.1016/j.canlet.2009.06.036]
180. O'Gorman DB, Costello M, Weiss J, Firth SM, Scott CD. Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells. Cancer Res 1999; 59: 5692-5694 [PMID: 10582686]
181. Chen Z, Ge Y, Landman N, Kang JX. Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells. BMC Cancer 2002; 2: 18 [PMID: 12149131 DOI: 10.1186/1471-2407-2-18]
182. Souza RF, Wang S, Thakar M, Smolinski KN, Yin J, Zou TT, Kong D, Abraham JM, Toretsky JA, Meltzer SJ. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene 1999; 18: 4063-4068 [PMID: 10435587 DOI: 10.1038/sj.onc.1202768]
183. Probst OC, Puxbaum V, Svoboda B, Leksa V, Stockinger H, Mikula M, Mikulits W, Mach L. The mannose 6-phosphate/insulin-like growth factor II receptor restricts the tumourigenicity and invasiveness of squamous cell carcinoma cells. Int J Cancer 2009; 124: 2559-2567 [PMID: 19195023 DOI: 10.1002/ijc.24236]
184. Li J, Sahagian GG. Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor. Oncogene 2004; 23: 9359-9368 [PMID: 15543235 DOI: 10.1038/sj.onc.1208039]
185. Schaffer BS, Lin MF, Byrd JC, Park JH, MacDonald RG. Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cells. Endocrinology 2003; 144: 955-966 [PMID: 12586773 DOI: 10.1210/en.2002-220751]
186. Sue SR, Chari RS, Kong FM, Mills JJ, Fine RL, Jirtle RL, Meyers WC. Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann Surg 1995; 222: 171-178 [PMID: 7639583 DOI: 10.1097/00000658-19 9508000-00009]
187. Kishimoto Y, Morisawa T, Kitano M, Shiota G, Horie Y, Suou T, Ito H, Kawasaki H, Hasegawa J. Loss of heterozygosity of the mannose 6-phosphate/insulin-like growth factor II receptor and p53 genes in human hepatocellular carcinoma. Hepatol Res 2001; 20: 68-83 [PMID: 11282487]
188. Kreiling JL, Montgomery MA, Wheeler JR, Kopanic JL, Connelly CM, Zavorka ME, Allison JL, Macdonald RG. Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer. FEBS J 2012; 279: 2695-2713 [PMID: 22681933 DOI: 10.1111/j.1742-4658.2012.08652.x]
189. Yamada T, De Souza AT, Finkelstein S, Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997; 94: 10351-10355 [PMID: 9294214 DOI: 10.1073/pnas.94.19.10351]
190. De Souza AT, Yamada T, Mills JJ, Jirtle RL. Imprinted genes in liver carcinogenesis. FASEB J 1997; 11: 60-67 [PMID: 9034167]
191. Han YL, Guo P, Sun MY, Guo L, Luan B, Kang J, Yan CH, Li SH. Secreted CREG inhibits cell proliferation mediated by mannose 6-phosphate/insulin-like growth factor II receptor in NIH3T3 fibroblasts. Genes Cells 2008; 13: 977-986 [PMID: 18691225 DOI: 10.1111/j.1365-2443.2008.01221.x]
192. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011; 71: 1029-1040 [PMID: 21245093 DOI: 10.1158/0008-5472.CAN-10-2274]
193. Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Clapéron A, Chrétien Y, Rey C, Scatton O, Soubrane O, Conti F, Praz F, Housset C, Rosmorduc O, Desbois-Mouthon C. Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Res 2013; 73: 3974-3986 [PMID: 23633480 DOI: 10.1158/0008-5472.CAN-12-3824]
194. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, Belfiore A. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999; 5: 1935-1944 [PMID: 10430101]
195. Zhou Q, Mao YQ, Jiang WD, Chen YR, Huang RY, Zhou XB, Wang YF, Shi Z, Wang ZS, Huang RP. Development of IGF signaling antibody arrays for the identification of hepatocellular carcinoma biomarkers. PLoS One 2012; 7: e46851 [PMID: 23071652 DOI: 10.1371/journal.pone.0046851]
196. Shao YY, Huang CC, Lin SD, Hsu CH, Cheng AL. Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res 2012; 18: 3992-3997 [PMID: 22623732 DOI: 10.1158/1078-0432.CCR-11-2853]
197. Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, Herrero JI, Castilla-Cortazar I, Frystyk J, Flyvbjerg A, Yoshizawa C, Jansen PL, Scharschmidt B, Prieto J. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005; 43: 630-636 [PMID: 16024131 DOI: 10.1016/j.jhep.2005.03.025]
198. Vera M, Sobrevals L, Zaratiegui M, Martinez L, Palencia B, Rodríguez CM, Prieto J, Fortes P. Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis. Gene Ther 2007; 14: 203-210 [PMID: 17024107 DOI: 10.1038/sj.gt.3302858]
199. Sobrevals L, Rodriguez C, Romero-Trevejo JL, Gondi G, Monreal I, Pañeda A, Juanarena N, Arcelus S, Razquin N, Guembe L, González-Aseguinolaza G, Prieto J, Fortes P. Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 2010; 51: 912-921 [PMID: 20198635 DOI: 10.1002/hep.23412]
200. Slijkhuis WA, Stadheim L, Hassoun ZM, Nzeako UC, Kremers WK, Talwalkar JA, Gores GJ. Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol 2005; 39: 333-338 [PMID: 15758629 DOI: 10.1097/01. mcg.0000155136.35315.de]
201. Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit 2011; 17: RA169-RA176 [PMID: 21804474]
202. Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, Xiao X, Peat TS, Newman J, Pilling PA, Phan T, Priebe I, Brierley GV, Kastrapeli N, Kopacz K, Martik D, Wassaf D, Rank D, Conley G, Huang Y, Adams TE, Cosgrove L. A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Mol Cancer Ther 2010; 9: 1809-1819 [PMID: 20515953 DOI: 10.1158/1535-7163. MCT-09-1134]
203. Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 2012; 72: 3-12 [PMID: 22215692 DOI: 10.1158/0008-5472.CAN-11-0550]
204. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002; 1: 347-355 [PMID: 12489851]
205. Lin SB, Hsieh SH, Hsu HL, Lai MY, Kan LS, Au LC. Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II. J Biochem 1997; 122: 717-722 [PMID: 9399573 DOI: 10.1093/oxfordjournals. jbchem.a021814]
206. Duplomb L, Chaigne-Delalande B, Vusio P, Raher S, Jacques Y, Godard A, Blanchard F. Soluble mannose 6-phosphate/insulin-like growth factor II (IGF-II) receptor inhibits interleukin-6-type cytokine-dependent proliferation by neutralization of IGF-II. Endocrinology 2003; 144: 5381-5389 [PMID: 12959977 DOI: 10.1210/en.2003-0607]
207. Gray SG, Kytola S, Lui WO, Larsson C, Ekstrom TJ. Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma. Int J Mol Med 2000; 5: 33-41 [PMID: 10601571]
208. Regel I, Eichenmüller M, Joppien S, Liebl J, Häberle B, Müller-Höcker J, Vollmar A, von Schweinitz D, Kappler R. IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors. Mol Cancer 2012; 11: 9 [PMID: 22401581 DOI: 10.1186/1476-4598-11-9]
209. Chen D, Siddiq A, Emdad L, Rajasekaran D, Gredler R, Shen XN, Santhekadur PK, Srivastava J, Robertson CL, Dmitriev I, Kashentseva EA, Curiel DT, Fisher PB, Sarkar D. Insulinlike growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC). Mol Ther 2013; 21: 758-766 [PMID: 23319057 DOI: 10.1038/mt.2012.282]
210. Zhang YC, Wang XP, Zhang LY, Song AL, Kou ZM, Li XS. Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. World J Gastroenterol 2006; 12: 3977-3982 [PMID: 16810743]
211. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13: 5549s-5555s [PMID: 17875788 DOI: 10.1158/1078-0432.CCR-07-1109]
212. Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007; 56: 343-357 [PMID: 16832681 DOI: 10.1007/s00262-006-0196-9]
213. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate SR. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgendependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005; 11: 3065-3074 [PMID: 15837762 DOI: 10.1158/1078-0432.CCR-04-1586]
214. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63: 8912-8921 [PMID: 14695208]
215. Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, Thung S, Moyano S, Toffanin S, Mínguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010; 52: 550-559 [PMID: 20206398 DOI: 10.1016/j.jhep.2010.01.015]
216. Abou-Alfa GK, Capanu M, O'Reilly EM, Ma J, Chou JF, Gansukh B, Shia J, Kalin M, Katz S, Abad L, Reidy-Lagunes DL, Kelsen DP, Chen HX, Saltz LB. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J Hepatol 2014; 60: 319-324 [PMID: 24045151 DOI: 10.1016/j.jhep.2013.09.008]
217. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073-5083 [PMID: 12941837]
218. Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 2010; 29: 251-262 [PMID: 19838209 DOI: 10.1038/onc.2009.316]
219. Spiliotaki M, Markomanolaki H, Mela M, Mavroudis D, Georgoulias V, Agelaki S. Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxelmediated anti-tumor effect. Lung Cancer 2011; 73: 158-165 [PMID: 21190751 DOI: 10.1016/j.lungcan.2010.11.010]
220. Geoerger B, Brasme JF, Daudigeos-Dubus E, Opolon P, Venot C, Debussche L, Vrignaud P, Vassal G. Anti-insulinlike growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma. Eur J Cancer 2010; 46: 3251-3262 [PMID: 20591650 DOI: 10.1016/j.ejca.2010.06.005]
221. Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, Amiot M. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 2009; 100: 366-369 [PMID: 19165200 DOI: 10.1038/sj.bjc.6604839]
222. Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay JY, LoRusso P, Mery-Mignard D, Soria JC. phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Ann Oncol 2013; 24: 784-791 [PMID: 23104723 DOI: 10.1093/annonc/mds511]
223. Rodon J, DeSantos V, Ferry RJ, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008; 7: 2575-2588 [PMID: 18790742 DOI: 10.1158/1535-7163.MCT-08-0265]
224. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005; 11: 2063-2073 [PMID: 15756033 DOI: 10.1158/1078-0432.CCR-04-1070]
225. Kim JG, Kang MJ, Yoon YK, Kim HP, Park J, Song SH, Han SW, Park JW, Kang GH, Kang KW, Oh do Y, Im SA, Bang YJ, Yi EC, Kim TY. Heterodimerization of glycosylated insulinlike growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS One 2012; 7: e33322 [PMID: 22438913 DOI: 10.1371/journal.pone.0033322]
226. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O'Connor M, Pirritt C, Sun Y, Yao Y, Arnold LD, Gibson NW, Ji QS. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009; 1: 1153-1171 [PMID: 21425998 DOI: 10.4155/fmc.09.89]
227. Zhao H, Desai V, Wang J, Epstein DM, Miglarese M, Buck E. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Mol Cancer Ther 2012; 11: 503-513 [PMID: 22161861 DOI: 10.1158/1535-7163.MCT-11-0327]
228. Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005; 7: R570-R579 [PMID: 15987464 DOI: 10.1186/bcr1028]
229. Deutsch E, Maggiorella L, Wen B, Bonnet ML, Khanfir K, Frascogna V, Turhan AG, Bourhis J. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. Br J Cancer 2004; 91: 1735-1741 [PMID: 15494718 DOI: 10.1038/sj.bjc.6602190]
230. Qi HW, Shen Z, Fan LH. Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line. Exp Ther Med 2011; 2: 1091-1095 [PMID: 22977626 DOI: 10.3892/etm.2011.324]
231. Yao WF, Liu JW, Sheng GL, Huang DS. Blockade of IGF-IR exerts anticancer effects in hepatocellular carcinoma. Mol Med Rep 2011; 4: 719-722 [PMID: 21567089 DOI: 10.3892/mmr.2011.486]
232. García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231-239 [PMID: 15050915 DOI: 10.1016/S1535-6108(04)00051-0]
233. Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherübl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 2006; 71: 1435-1448 [PMID: 16530734 DOI: 10.1016/j.bcp.2006.02.006]
234. Chang AY, Wang M. In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. Anticancer Drugs 2013; 24: 251-259 [PMID: 23187461 DOI: 10.1097/CAD.0b013e32835ba289]
235. Sabbatini P, Rowand JL, Groy A, Korenchuk S, Liu Q, Atkins C, Dumble M, Yang J, Anderson K, Wilson BJ, Emmitte KA, Rabindran SK, Kumar R. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res 2009; 15: 3058-3067 [PMID: 19383820 DOI: 10.1158/1078-0432.CCR-08-2530]
236. Lin RX, Wang ZY, Zhang N, Tuo CW, Liang QD, Sun YN, Wang SQ. Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin-like growth factor receptor in vitro and in an orthotopic model. Hepatol Res 2007; 37: 366-375 [PMID: 17441810 DOI: 10.1111/j.1872-034X.2007.00055.x]